Alle Storys
Folgen
Keine Story von Wyeth Pharmaceuticals mehr verpassen.

Wyeth Pharmaceuticals

New Evidence Advocates the use of Enbrel to Combat and Effectively Control the Debilitating Symptoms of Psoriasis

Istanbul, Turkey (ots/PRNewswire)

- New Studies Provide Clinical Support for More Flexible and
Convenient Dosing Options for Patients
New data from key clinical trials presented today at the 5th
European  Academy of Dermatology and Venereology (EADV) Spring
Symposium in Istanbul,  demonstrate that Enbrel(R) (etanercept) is a
convenient and effective  treatment which helps patients achieve
sustained and repeatable reprieve from  the physically and
psychologically debilitating symptoms of psoriasis.
    Results from two key clinical trials were reported:
    - CRYSTEL study showed that continuous Enbrel therapy was at least as
      effective and safe as paused therapy in psoriasis patients and both
      treatment regimens improved Physician Global Assessment (PGA) scores
      and patient satisfaction.
    - The 318 study investigated patients with serious patient-reported
      outcome (PRO) impairment and showed that administration of Enbrel 50mg
      once weekly resulted in significant PRO improvements.
Commenting on the overall impact of the new study details,
investigator Professor Christopher Griffiths, Professor of
Dermatology, University of Manchester, Manchester, UK, noted
"Psoriasis can be extremely distressing and requires a life-time of
treatment. There is a real need for patient-centred management with
early and effective treatment intervention. These study results add
to the body of evidence demonstrating that Enbrel (etanercept) is
safe and effective as either a continuous or intermittently used
therapy in patients with psoriasis. Furthermore, the once-weekly
study findings indicate that a more convenient treatment regime is a
realistic option in the near future for patients with this disabling
disease."
CRYSTEL study details presented at Spring EADV
In the CRYSTEL study, patients with moderate-to-severe psoriasis
were randomised in an open-label study and received Enbrel, either
continuously for 54 weeks or paused in a treat-to-response fashion.
- Continuous Enbrel therapy was at least as effective and safe
      as paused therapy in psoriasis patients - both treatment regimens
      improved PGA scores and patient satisfaction, with satisfaction
      maintained during the re-treatment period in the paused group.
    - Patients treated with Enbrel showed sustained improvements in
      Dermatology Life Quality Index (DLQI) for up to 54 weeks.
    - Significant improvement in nail psoriasis was seen in Enbrel
      treated patients as early as Week 12 and was sustained for up to 54
      weeks. Greater improvement in nail psoriasis was seen with continuous
      treatment; however, both groups showed continuing and significant
      improvement over 54 weeks, and the paused arm showed repeat response
      after re-treatment.
    - Significant improvement in scalp psoriasis was seen in Enbrel
      treated patients as early as Week 3 and was sustained for up to 54
      weeks. Greater improvement in Psoriasis Scalp Score (PSS) was seen with
      continuous treatment; however, improvement in the paused group was also
      seen and was maintained after re-treatment.
Enbrel once-weekly study details presented at Spring EADV
Data from a separate trial show that the new option of Enbrel
once-weekly could also help to provide greater flexibility and
convenience to improve the quality of life for patients with
moderate-to-severe psoriasis. Patients with moderate-to-severe
psoriasis entered this trial with serious PRO impairment, with
Dermatology Life Quality Index (DLQI) (QoL indices) comparable to
that of patients with severe chronic obstructive pulmonary disease
(COPD). At week 12, patients receiving Enbrel 50 mg QW had
significant improvements in PROs compared with patients receiving
placebo. After 24 weeks of etanercept treatment, patients' serious
PRO impairment was largely abated, consistent with improvements in
clinical measures reported elsewhere.
Impact of Psoriasis
Across Europe 5.1 million people are estimated to have psoriasis,
a distressing chronic inflammatory disease. Approximately 80 per cent
of these patients have plaque psoriasis, which is characterised by
red, scaly patches. Psoriasis can be extremely distressing and has a
significant impact on patients' quality of life. It is a condition
which is frequently physically and psychologically disabling - in
adults it is associated with an increased risk of obesity, type 2
diabetes, liver disease and clinical depression.
Mara Maccarone, President of the Pan-European Psoriasis Patients
Organisation Forum (PE.Pso.POF) commented, "Recently, research we
conduced in the form of a pan-European patient survey highlighted the
very real impact that psoriasis has on the daily lives of individuals
and how in reality many patients delay seeking treatment. It is
important that patients are given appropriate and effective
treatments for their psoriasis as early as possible. With the advent
of newer systemic treatments psoriasis patients have greater options
tailored to their needs that can achieve skin clearance that will
dramatically improve their lives. Our survey shows many patients who
are eligible for biologics are not getting these treatments and are
remaining on sub-optimal treatments for prolonged periods of time"
Notes to Editors
About Enbrel
Enbrel is a fully human soluble tumour necrosis factor (TNF)
receptor. Enbrel was first approved in 1998 for moderate to severe
rheumatoid arthritis and has since been used in nearly 500,000
patients worldwide across indications.
Enbrel in the EU is approved for the following indications:
Rheumatoid arthritis
Enbrel in combination with methotrexate is indicated for the
treatment of moderate to severe active rheumatoid arthritis in adults
when the response to disease-modifying antirheumatic drugs, including
methotrexate (unless contraindicated), has been inadequate.
Enbrel can be given as monotherapy in case of intolerance to
methotrexate or when continued treatment with methotrexate is
inappropriate.
Enbrel is also indicated in the treatment of severe, active and
progressive rheumatoid arthritis in adults not previously treated
with methotrexate.
Enbrel, alone or in combination with methotrexate, has been shown
to reduce the rate of progression of joint damage as measured by
X-ray and to improve physical function.
Polyarticular juvenile idiopathic arthritis
Treatment of active polyarticular juvenile idiopathic arthritis
in children and adolescents aged 4 to 17 years who have had an
inadequate response to, or who have proved intolerant of,
methotrexate. Enbrel has not been studied in children aged less than
4 years.
Psoriatic arthritis
Treatment of active and progressive psoriatic arthritis in adults
when the response to previous disease-modifying antirheumatic drug
therapy has been inadequate. Enbrel has been shown to improve
physical function in patients with psoriatic arthritis, and to reduce
the rate of progression of peripheral joint damage as measured by
X-ray in patients with polyarticular symmetrical subtypes of the
disease.
Ankylosing spondylitis
Treatment of adults with severe active ankylosing spondylitis who
have had an inadequate response to conventional therapy.
Plaque psoriasis
Treatment of adults with moderate to severe plaque psoriasis who
failed to respond to, or who have a contraindication to, or are
intolerant to other systemic therapy including cyclosporine,
methotrexate or PUVA
About Wyeth:
Wyeth is one of the world's largest research-based pharmaceutical
and health care products companies. It is a leader in the discovery,
development, manufacturing, and marketing of prescription drugs and
over-the-counter medications. It is also a global leader in vaccines,
biotechnology and animal health care.
Please ensure that you go to www.wyeth.eu website and register to
enable you to view information and updates on the latest Wyeth news
and get access to supporting materials to help keep you up-to-date
with comprehensive information about Wyeth and our therapy areas.
If you subscribe to receive our emails you will get updates as
soon as new content added to the site. Note you will be able to
unsubscribe at any time and we will not pass your details to any
third party.
References
For full details of references, please contact Karen Crum at
OgilvyHealthPR (Direct Tel: +44(0)207-108-6411 / Email: 
karen.crum@ohpr.co.uk)

Contact:

Wyeth: Gill Markham, Communications - Europe, Middle East and Africa,
Direct Tel: +44(0)1628-692536, Email: markhagl@wyeth.com; Danielle
Halstrom, Communications - Global, Tel: +1-484-865-2020, Email:
halstrd@wyeth.com; OgilvyHealthPR:, Karen Crum, Direct Tel:
+44(0)207-108-6411, Email: karen.crum@ohpr.com; Jodi Lewis, Direct
Tel: +44(0)207-108-6086, Email: jodi.lewis@ohpr.com

Weitere Storys: Wyeth Pharmaceuticals
Weitere Storys: Wyeth Pharmaceuticals